Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Clinical trial NCT05673200 · SUSPENDED

Trial details

NCT number: NCT05673200
Sponsor: National Cancer Institute (NCI)
Status: SUSPENDED
Phase: Phase 1
Study type: INTERVENTIONAL

Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Triple-Negative Breast Carcinoma Unresectable Triple-Negative Breast Carcinoma

Start date: 2023-09-25
Primary completion: 2027-02-23
Enrollment: 32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.